Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study

Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study / Necchi, A; Lo Vullo, S; Raggi, D; Perrone, F; Giannatempo, P; Calareso, G; Togliardi, E; Nicolai, N; Piva, L; Biasoni, D; Catanzaro, M; Torelli, T; Stagni, S; Colecchia, M; Busico, A; Pennati, M; Zaffaroni, N; Mariani, L; Salvioni, R. - In: UROLOGIC ONCOLOGY. - ISSN 1078-1439. - 36:1(2018), pp. 30451-30459. [10.1016/j.urolonc.2017.08.020]